A multicenter study of the impella device for mechanical support of the systemic circulation in pediatric and adolescent patients

Catheterization and Cardiovascular Interventions - Tập 90 Số 1 - Trang 124-129 - 2017
V. Vivian Dimas1,2, Brian H. Morray3,2, Dennis W. Kim4, Christopher S. Almond5, Shabana Shahanavaz6, Sebastian C. Tume7, Lynn F. Peng5, Doff B. McElhinney8, Henri Justino7
1Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX
2These authors contributed equally to the manuscript
3Division of Cardiology, Seattle Children's Hospital, Seattle, WA
4Division of Pediatric Cardiology, Children's Healthcare of Atlanta, Emory University, Atlanta, GA
5Division of Pediatric Cardiology, Lucille Packard Children's Hospital at Stanford, Palo Alto, CA
6Division of Pediatric Cardiology, Washington University School of Medicine, St. Louis, MO
7Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX
8Department of Cardiothoracic Surgery, Lucille Packard Children's Hospital at Stanford, Palo Alto, CA

Tóm tắt

ObjectivesThe objective was to review the use of Impella devices (Abiomed Inc, Danvers, MA) for temporary circulatory support in pediatric and adolescent patients (age ≤ 21 yrs).BackgroundOptions for minimally invasive circulatory support in children are limited, and published data are confined to case reports and small case series.MethodsThis was a retrospective, multicenter review of Impella implants in pediatric and adolescent patients from 2009‐15, using standardized data collection and INTERMACS definitions.ResultsA total of 39 implants were performed in 38 patients from 16 centers. Median age and weight were 16 yrs (4–21 yrs) and 62 kg (15–134 kg). The primary indication for implant was cardiogenic shock in 28 patients (72%). Cardiac allograft rejection, myocarditis, or cardiomyopathy were the underlying diagnosis in 23 patients (59%); 11 patients had congenital heart disease. The median duration of support was 45 hr (1–1224 hr). Indications for explant included ventricular recovery in 16 patients, transition to another device in 12, death in 5, and transplant in 1. Survival was 85% at 7 days and 68% at 30 days. Major adverse events occurred in 8 patients: hemolysis in 3, bleeding in 2, stroke in 1 (unclear if related to Impella), sepsis in 1, and critical leg ischemia in 1. An increase in aortic regurgitation was noted in three patients, with no evidence of valve injury.ConclusionTemporary circulatory support with Impella devices is feasible in pediatric and adolescent patients, with acceptable risk profiles. More experience and follow up is needed to improve technical performance and patient selection. © 2017 Wiley Periodicals, Inc.

Từ khóa


Tài liệu tham khảo

10.1016/j.jacc.2015.03.036

10.1161/CIRCULATIONAHA.110.945055

10.1016/j.jtcvs.2013.08.044

Abiomed. Abiomed Impella therapy receives FDA approval for cardiogenic shock after heart attack or heart surgery [press release]. April 7 2016.

FDA. Summary of Safety and Effectiveness Data (SSED) ‐ HRPCI.http://www.accessdatafda.gov/cdrh_docs/pdf14/P140003S005B.pdf.

FDA. Summary of Safety and Effectiveness Data (SSED) ‐ AMI/CS PCCS.http://www.accessdatafda.gov/cdrh_docs/pdf14/P140003S005B.pdf.

10.1016/j.jacc.2015.10.017

10.4244/EIJV11I12A261

10.1002/ccd.25042

10.1016/j.healun.2009.06.020

10.1111/j.1399-3046.2011.01578.x

10.1161/CIRCULATIONAHA.113.005574

10.1056/NEJMoa1208410

10.1093/eurheartj/ehn602

10.1016/j.jacc.2008.05.065

Premarket Assessment of Pediatric Medical Devices ‐ Guidelines for Industry and Food and Drug Administration Staff. Issued March 24 2014.http://www.fda.gov/RegulatoryInformation/Guidances/ucm089740.htm.

10.1016/j.healun.2016.03.005

10.1016/j.healun.2016.01.1227

10.1016/j.jtcvs.2013.11.033

10.1016/j.athoracsur.2013.07.053

10.1097/MAT.0000000000000290

10.1161/CIRCHEARTFAILURE.112.967224

10.1016/j.jchf.2015.06.010

10.1097/PCC.0000000000000276

Thông tin
Thông tin xuất bản

Catheterization and Cardiovascular Interventions

Tập 90 Số 1

124-129

Thông tin tác giả